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Abstract 
In the present study, we observed that the adenocarcinoma component in the mucosa was 
continuous with neuroendocrine carcinoma (NEC) in the deeper layers; this suggests the 
normal course of NEC carcinogenesis at the histological level. A 72-year-old man was 
admitted to our hospital with a chief complaint of tarry stools. Endoscopic examination of 
the upper gastrointestinal tract revealed a 2-cm tumor, with a deep central depression, 
surrounded by a smooth elevated area, in the middle of the stomach body. A biopsy showed 
that the tumor was a moderately differentiated gastric adenocarcinoma. The patient 
underwent total gastrectomy and standard lymph node dissection. The resected tumor was 
a 3.5 × 2.5 cm type 2 lesion. It comprised two elements at the histological level: (i) a 
moderately differentiated adenocarcinoma in the superficial portion of the mucous 
membrane layer, and (ii) NEC-like cells with dark, round nuclei and scant cytoplasm, 
presenting a solid and trabecular pattern, in the submucosal and muscularis propria layers. 
Immunohistochemical findings showed that the NEC-like cells were diffusely positive for 
chromogranin A, synaptophysin, neural cell adhesion molecule, and neuron-specific enolase, 
but were negative for carcinoembryonic antigen. The Ki-67 labeling index was 95%. The final 
pathological diagnosis was gastric NEC with an adenocarcinoma component and a high 
cellular proliferative potential. 
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Introduction 
Neuroendocrine carcinoma (NEC) rarely occurs in the gastrointestinal tract and 
accounts for approximately 1% of cancers in the esophagus, 0.2% in the colon, and  
0.1–0.4% in the stomach [1, 2]. NEC has been variously termed ‘endocrine cell 
carcinoma’, ‘small cell carcinoma’, ‘atypical carcinoid’, and ‘oat-cell carcinoma’ [3]. 
Gastric NEC is characterized by endocrine cell differentiation and classified as either 
a pure-type tumor or a composite-type tumor containing an admixture of 
adenocarcinoma and/or differentiated squamous type cells [4]. Gastric NEC arises 
predominantly from endocrine precursor cell clones that develop in the preceding 
adenocarcinoma component. These clones transform into NEC and the NEC develops 
rapidly in the submucosal and deeper layers [5]. Therefore, it is difficult to make a 
definitive diagnosis of NEC by endoscopic biopsy. Immunohistochemical staining for 
several neuroendocrine markers – chromogranin A, synaptophysin, etc. – is helpful 
in making a definite diagnosis of NEC. The prognosis of gastric NEC is extremely 
poor, and lymph node and liver metastases are observed frequently. However, there 
is no standardized chemotherapy. In the present study, we observed that the 
adenocarcinoma component in the mucosa was continuous with the NEC in the deeper 
layers; this suggests the normal course of NEC carcinogenesis at the histological level. 
Case Report 
The patient was a 72-year-old man who was born healthy. He was admitted to our hospital 
with a chief complaint of tarry stools. Physical examination revealed anemia in the palpebral 
conjunctiva, but did not show a mass in the abdomen or enlargement of any superficial lymph nodes. 
The hemoglobin level was 9.8 g/dl and the albumin level was 3.2 g/dl, but the other hematological 
tests, including those for the serum levels of tumor markers such as carcinoembryonic antigen (CEA) 
and carbohydrate antigen 19-9, yielded normal results. Endoscopic examination of the upper 
gastrointestinal tract revealed a 2-cm tumor, with a deep central depression, surrounded by a smooth 
elevated area, in the middle of the stomach body. A biopsy showed that the tumor was a moderately 
differentiated gastric adenocarcinoma (fig. 1a). Ultrasound endoscopic examination showed that the 
tumor invaded the subserosa (fig. 1b). Radiography of the upper gastrointestinal tract showed the 
presence of a mass with central ulceration and a clear margin, surrounded by a smooth elevated area, 
in the posterior wall of the stomach body. Computed tomography (CT) showed two lymph nodes each 
measuring 10 mm in diameter on the lesser curve of the stomach, suggestive of metastasis, but we 
neither observed a thickened gastric wall, which could be due to the tumor, nor distant metastasis. 
Total gastrectomy, standard lymph node dissection and Roux-en-Y reconstruction with a jejunal 
pouch were performed without any complication. 
Gross pathological examination showed that the tumor was a 3.5 × 2.5 cm type 2 lesion in the 
middle of the posterior wall of the stomach body (fig. 2a). Microscopic examination of the resected 
specimen revealed a large ulcerated tumor invading the muscularis propria, with vascular and 
lymphatic invasions. The NEC had also metastasized to the regional lymph nodes. Hematoxylin-eosin 
staining showed that the tumor comprised two elements at the histological level: (i) a moderately 
differentiated adenocarcinoma in the superficial portion of the mucous membrane layer, and 
(ii) NEC-like cells with dark, round nuclei and scant cytoplasm, presenting a solid and trabecular 
pattern, in the submucosal and muscularis propria layers (fig. 2b). Immunohistochemical findings 
showed that the NEC-like cells were diffusely positive for chromogranin A, synaptophysin, neural 
cell adhesion molecule (NCAM), and neuron-specific enolase (NSE), but were negative for CEA. The 
Ki-67 labeling index was 95% (fig. 3). The final pathological diagnosis was gastric NEC with an 
adenocarcinoma component and a high cellular proliferative potential.  
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Adjuvant chemotherapy consisting of S-1 (tegafur/gimeracil/oteracil potassium) at a dose of 
120 mg was administered orally. 6 months after the operation, the patient underwent a CT, the results 
of which did not show recurrence or metastasis. 
Discussion 
Most digestive neuroendocrine tumors (NETs) are referred to as carcinoids. 
Recently, a new classification system for digestive NETs has been formulated and is 
presented in the 2010 revision of the WHO classification of digestive tumors [6]. It 
recognizes five main categories: NET G1, NET G2, small cell-type NEC, large cell-type 
NEC, and mixed adenoneuroendocrine carcinoma. This classification is based on 
cellular atypia, nuclear abnormalities, the number of mitotic figures, and the Ki-67 
labeling index by which the tumor’s proliferative activity can be determined. Our 
patient was diagnosed with gastric small cell-type NEC on the basis of the cells’ high 
proliferative potential and scant cytoplasm. Moreover, cytoplasmic argyrophilia and 
presence of structural neurosecretory granules support this diagnosis; however, 
previous studies have reported that several tumors did not have these features [4, 7]. 
Therefore, an immunohistochemically positive staining for several neuroendocrine 
markers – chromogranin A, synaptophysin, synaptic vesicle protein, Leu 7 (CD57), NSE, 
protein gene product 9.5 (PGP 9.5), NCAM (CD56), and cytokeratin – is helpful in 
making a definite diagnosis of NEC, in contrast to negative staining for CEA [4, 8]. The 
patient in our study, too, was positive for some of these neuroendocrine markers. 
NEC in the gastrointestinal tract occasionally shows multidirectional differentiation, 
with adenocarcinoma and/or squamous cell proliferation [4, 9, 10]. Nishikura et al. [5] 
demonstrated that 70.6% of gastric NEC cases included an adenocarcinoma component 
in the mucosa and/or submucosa. Furthermore, gastric NEC arises predominantly from 
endocrine precursor cell clones that develop in the preceding adenocarcinoma 
component. These clones transform into NECs during rapid clonal expansion, and the 
NEC develops rapidly in the submucosal and deeper layers [5]. Similar to this 
observation, our patient had an adenocarcinoma component that was restricted to the 
mucosal surface, whereas the NEC was found in the deeper layers. Moreover, the two 
components were continuous; this finding suggested a NEC carcinogenesis at the 
histological level. 
Gastric NEC invades lymphatic and vascular lumens and frequently metastasizes 
to the lymph nodes and liver, even during the early stages, because of its aggressive 
biological behavior [4]. Therefore, intensive chemotherapy, with or without surgery, 
is recommended for gastric NEC at any stage [10]. Previously, cisplatin and etoposide 
(PE) and cyclophosphamide, doxorubicin, and etoposide (CDE) combinations have 
been employed for the chemotherapeutic treatment of NEC [11, 12]; however, the 
chemotherapy has not yet been standardized. Recently, Okita et al. [13] reported that 
cisplatin plus irinotecan regimens elicited a good response in 12 cases of metastatic 
or recurrent gastric NEC (the response rate was 75%, the median progression-free 
survival time was 212 days, and the median survival time was 679 days). The 
neoadjuvant or adjuvant first-line chemotherapy regimens used for the treatment of 
gastric adenocarcinoma (S-1 and S-1/cisplatin) have been effective for treating gastric 
NEC [14, 15]. However, no conclusions can be drawn regarding the most effective 
regimen because of the small number of patients.  
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Conclusion 
Gastric NEC can coexist with an adenocarcinoma component at the mucosal surface. 
Therefore, it is difficult to make a definitive diagnosis of NEC preoperatively by 
endoscopic biopsy. The tumor in our patient was resected curatively without distant 
metastasis, and this may explain the disease-free survival of the patient for 8 months 
after the operation. However, we think that it is necessary to follow up this patient 
carefully and administer adjuvant chemotherapy, keeping in mind the poor prognosis 
and high cellular proliferative potential of gastric NEC. 
 
 
 
 
 
 
Fig. 1. a Endoscopic examination of the upper gastrointestinal tract revealed a 2-cm tumor, with a 
deep central depression, surrounded by a smooth elevated area, in the middle of the stomach body. 
b Ultrasound endoscopic examination showed that the tumor invaded the subserosa. 
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Fig. 2. a Gross pathological examination showed that the tumor was a 3.5 × 2.5 cm type 2 lesion in the 
middle of the posterior wall of the stomach body. b At microscopic examination the tumor comprised 
two elements at the histological level (hematoxylin-eosin staining, ×2): (i) A moderately differentiated 
adenocarcinoma in the superficial portion of the mucous membrane layer (×40). (ii) NEC-like cells 
with dark, round nuclei and scant cytoplasm, presenting a solid and trabecular pattern, in the 
submucosal and muscularis propria layers (×40). 
 
 
 
Fig. 3. Immunohistochemical findings (×40). The NEC-like cells were diffusely positive for 
chromogranin A (a), synaptophysin (b), NCAM (d) and NSE (e), but were negative for CEA (c). The 
Ki-67 labeling index (f) was 95%. 
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